Clinical Scorecard: Prevalence of Meibomian Gland Dysfunction in the Upper Eyelid Among Postmenopausal Women with Primary Acquired Nasolacrimal Duct Obstruction

At a Glance

Key Highlights

• PANDO predominantly affects postmenopausal women, with a female-to-male incidence ratio of up to 3:1.
• Meibomian gland dysfunction (MGD) is a significant factor in evaporative dry eye disease, particularly in postmenopausal individuals.
• 20% to 27% of patients with lacrimal duct obstruction report dry eye symptoms post-surgery.
• Structural and functional alterations in meibomian glands are observed in postmenopausal women with PANDO.
• The study aims to investigate the differential involvement of meibomian glands in upper and lower eyelids.
• Emerging evidence supports a potential association between PANDO and ocular surface damage.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of PANDO based on epiphora, confirmed nasolacrimal duct obstruction, and absence of secondary causes.

Management

• Evaluate ocular surface status in patients with PANDO during episodes of epiphora.
• Consider anatomical differences between upper and lower eyelids when assessing MGD.

Monitoring & Follow-up

• Assess meibomian gland loss and tear film stability in postmenopausal women with PANDO.

Risks

• Patients may have pre-existing ocular surface damage before surgical intervention for PANDO.

Patient & Prescribing Data

Postmenopausal women diagnosed with PANDO.

Targeted therapeutic strategies may be developed based on the correlation between meibomian gland parameters and tear film function.

Clinical Best Practices

• Conduct thorough ocular examinations to assess meibomian gland function and tear film stability.
• Consider hormonal factors when evaluating postmenopausal women with PANDO.
• Evaluate tear film stability in relation to meibomian gland function.

Related Resources & Content

• Study on PANDO and MGD